The views of stakeholders on controlled access schemes for high-cost antirheumatic biological medicines in Australia

BACKGROUND: In Australia, government-subsidised access to high-cost medicines is "targeted" to particular sub-sets of patients under the Pharmaceutical Benefits Scheme to achieve cost-effective use. In order to determine how this access system could be improved, the opinions of key stakeho...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Christine Y, Ritchie, Jan, Williams, Ken, Day, Ric
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2231358/
https://www.ncbi.nlm.nih.gov/pubmed/18096055
http://dx.doi.org/10.1186/1743-8462-4-26

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2231358/
https://www.ncbi.nlm.nih.gov/pubmed/18096055
http://dx.doi.org/10.1186/1743-8462-4-26

Ejemplares similares